Welcome to our dedicated page for Silo Pharma news (Ticker: SILO), a resource for investors and traders seeking the latest updates and insights on Silo Pharma stock.
Silo Pharma develops novel therapeutics and drug-delivery systems for stress-induced psychiatric disorders, chronic pain and central nervous system diseases, while also disclosing activity in cryptocurrency treasury and AI infrastructure initiatives. Company news frequently centers on SPC-15, an intranasal serotonin 5-HT4 receptor agonist program for PTSD and anxiety, as well as other pipeline work involving psychedelic-derived and traditional therapeutic approaches.
Recurring updates include patent allowances and applications in key jurisdictions, FDA and federal-policy context for psychedelic medicines, clinical-development planning, and new CNS discovery initiatives such as ibogaine-based approaches for traumatic brain injury. Corporate news also covers common-stock repurchase authorization, equity-financed asset purchases, the QwikAgents AI-agent platform, and cryptocurrency-related software assets.
Silo Pharma (NASDAQ: SILO) reported progress on its lead PTSD candidate SPC-15 and launched a digital assets treasury program. Key biopharma updates include positive bioanalytical and large-animal safety/toxicology results for a 7-day study, completion of an IND-enabling GLP toxicology/toxicokinetic study (data expected in early 2026), finalizing a drug-device study for a microchip-based nasal spray, and patent expansion in the U.S., Australia and Japan. On the crypto side, Silo began purchases in Sept–Oct 2025 (BTC, ETH, SOL, RSC), appointed a lead crypto advisor, formed a crypto advisory board, and engaged Fireblocks for institutional custody and operations.
Catalysts include FDA follow-up in November 2025 and IND submission planning in 2026.
Silo Pharma (NASDAQ: SILO) announced on October 8, 2025 its initial purchase of Bitcoin as part of a crypto reserve strategy aimed at multi-chain asset growth. The company said this purchase complements earlier crypto buys in Ethereum, RSC, and Solano tokens and signals conviction in Bitcoin as a store of value and a hedge against market volatility. Management indicated Silo will continue building a diversified digital-asset treasury to support the company’s multi-chain growth approach.
Silo Pharma (NASDAQ: SILO) announced on October 6, 2025 that it purchased ResearchCoin (RSC) as part of an expanded digital-assets treasury strategy to gain exposure to decentralized science (DeSci).
RSC is the native token of ResearchHub, a platform co-founded in 2019 by Coinbase CEO Brian Armstrong, designed to reward sharing, peer review, and curation of scientific knowledge. Silo characterized the move as an effort to diversify assets and participate in token-based models that could unlock value in the global research economy through tokenization of funding and intellectual property.
The announcement frames DeSci as a long-term growth opportunity that could allow earlier liquidity and exit options for research-backed innovations, but the company did not disclose the size, valuation, or timing of the RSC purchase.
Silo Pharma (NASDAQ:SILO), a developmental stage biopharmaceutical company, has completed its previously announced registered direct offering, raising $2.5 million in gross proceeds. The offering consisted of 2,857,143 shares of common stock priced at $0.875 per share.
In a concurrent private placement, the company issued unregistered warrants to purchase up to 2,857,143 shares at an exercise price of $0.75 per share. The warrants are immediately exercisable and will expire five years after the registration statement becomes effective. H.C. Wainwright & Co. served as the exclusive placement agent, and the proceeds will be used for working capital and general corporate purposes.
Silo Pharma (Nasdaq: SILO), a developmental stage biopharmaceutical company, has announced a $2.5 million registered direct offering priced at-the-market under Nasdaq rules. The company will sell 2,857,143 shares of common stock at $0.875 per share.
Additionally, Silo will issue unregistered warrants in a concurrent private placement to purchase up to 2,857,143 shares at an exercise price of $0.75 per share. These warrants will be immediately exercisable and expire after five years. The offering, managed by H.C. Wainwright & Co. as exclusive placement agent, is expected to close around October 1, 2025.
The company plans to use the net proceeds for working capital and general corporate purposes.
Silo Pharma (Nasdaq: SILO), a developmental-stage biopharmaceutical and cryptocurrency treasury company, has initiated implementation of its strategic agreement with Fireblocks for crypto treasury management. Fireblocks, a leading digital asset custody platform, has facilitated over $10 trillion in secure transfers to date.
The partnership aims to establish institutional-grade infrastructure for buying, staking, and managing digital assets at scale. Fireblocks' multi-layer security framework incorporates multi-party computation technology, Intel SGX, a signature policy engine, and deposit address authentication network.
Silo Pharma (Nasdaq: SILO), a developmental-stage biopharmaceutical and cryptocurrency treasury company, has partnered with Fireblocks as its institutional crypto treasury platform custodian. The strategic agreement aims to enhance Silo's digital asset management capabilities for Bitcoin, Ethereum, and Solana.
Fireblocks, which has facilitated over $6 trillion in secure transfers, will provide enterprise-grade security through its multi-layer framework, combining multi-party computation technology, Intel SGX, and deposit address authentication. This infrastructure will support Silo's long-term strategy for buying, staking, trading, and managing digital assets.
Silo Pharma (Nasdaq: SILO) has initiated its cryptocurrency treasury strategy with its first purchases of Ethereum (ETH) and Solana (SOL) tokens. The company, which operates as a developmental-stage biopharmaceutical and cryptocurrency treasury company, plans to stake these tokens for revenue generation and capital appreciation.
CEO Eric Weisblum expressed confidence in decentralized blockchain and DeFi platforms, highlighting the company's commitment to incorporating digital assets into its treasury holdings. This strategic move aims to support Silo's biopharmaceutical assets development while positioning the company for blockchain and real-world asset tokenization initiatives.
Silo Pharma (Nasdaq: SILO) has strengthened its intellectual property portfolio with a new Japanese patent (No. 7683882) granted to its research partner Columbia University for SPC-15, the company's lead PTSD treatment. The patent, which follows a recent Australian patent grant, covers serotonin 4 receptor agonists for stress treatment.
The intranasal PTSD treatment, exclusively licensed to Silo by Columbia University, gains additional international protection through this patent issuance, supporting the company's development and regulatory strategy for this novel therapy.
Silo Pharma (Nasdaq: SILO) has secured a significant patent in Australia (patent number 2020271839) for its PTSD drug candidate SPC-15. The patent, granted to Silo's research partner Columbia University, covers the invention "Prophylactic efficacy of serotonin 4 receptor agonists against stress" which is exclusively licensed to Silo.
SPC-15, the company's lead asset, is being developed as an intranasal treatment targeting post-traumatic stress disorder (PTSD). The patent strengthens Silo's global intellectual property portfolio and supports their plans for clinical trial development of this innovative therapeutic approach to preventing stress-induced disorders.